FrederickEdwardMillardMD

Oncology • La Jolla, CA

Genitourinary Oncology

Clinical Professor of Medicine at UC San Diego Moores Cancer Center

Join to view full profile

Dr. Millard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Millard's full profile

Already have an account?

Office
3855 Health Sciences Drive
Moores UCSD Cancer Center , MC 0987
La Jolla, CA 92093
Phone+1 858-822-6185

Fax+1 858-249-0905

Education & Training

Naval Medical Center (San Diego)Fellowship, Hematology and Medical Oncology, 1984 - 1987
Naval Medical Center (San Diego)Residency, Internal Medicine, 1982 - 1984
Naval Medical Center (San Diego)Internship, Internal Medicine, 1980 - 1981
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1980

Certifications & Licensure

CA State Medical License 1984 - 2026
PA State Medical License 1990 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma Start of enrollment: 2003 Apr 01
Completed
Phase 1
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

199 citations
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Peter F. Coccia, Alberto S. Pappo, Lynda K. Beaupin, Virginia F. Borges, Scott C. Borinstein
Journal of the National Comprehensive Cancer Network. 2018-01-01
81 citations
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I. Milowsky, Christian Dittrich, Ignacio Duran, Satinder Jagdev, Frederick Millard
European Journal of Cancer. 2014-12-01
24 citations
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.
Charles Field, Brittney Cotta, Juan Jimenez, Brian R. Lane, Kendrick Yim
Clinical Genitourinary Cancer. 2019-01-30

Professional Memberships

American Society of Clinical Oncology - ASCO
Member